Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

A progressive neurological disorder affecting 10 million people globally, Parkinson’s can cause disruptive symptoms such as ...

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

Groundbreaking new research released from Northwestern Medicine discovered that a usually harmless virus in the blood, may be ...

A team of neuroscientists in Australia has found that restoring copper levels in the brain dramatically reduced Parkinson-like damage in mice. The approach restored a protein’s function, and the same ...

Researchers at the Lawson Health Research Institute, part of St. Joseph’s Health Care London, are studying Ambroxol, a cough ...

The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...